Physician profile
Ujjwal Kumar
NPI 1235570805
$4,097.65
in general payments reported to CMS, 2019-2025
24 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.35 · 2020: $136 · 2021: $692 · 2022: $214 · 2023: $458 · 2024: $1,325 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148 · Travel and Lodging: $778 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.56 |
| Travel and Lodging | $778.20 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,220.70 | 2021-2024 | Spyglass, Axios, Dreamtome Rx 49 |
| Abbvie INC. | $1,146.48 | 2020-2025 | |
| Janssen Biotech, INC. | $314.09 | 2021-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.14 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $172.40 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.11 | 2020-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $120.96 | 2023-2025 | Dupixent |
| Celgene Corporation | $116.09 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $90.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $85.23 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $75.13 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $64.78 | 2020-2023 | Linzess |
| Braintree Laboratories, INC. | $62.18 | 2022-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $52.17 | 2020-2021 | |
| Gilead Sciences, INC. | $45.88 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.13 | 2023-2024 | Dificid |
| Olympus America INC. | $29.45 | 2025 | Visiglide |
| Aimmune Therapeutics, INC. | $24.10 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals Lp | $23.30 | 2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $15.67 | 2022 | |
| Genzyme Corporation | $14.92 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.07 | 2025 | Voquezna |
| Allergan, INC. | $13.44 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ujjwal Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.